The study identified several factors influencing antibody kinetics: Moderna consistently induced higher anti-S1 IgG levels compared to Pfizer at both two and eight months post-vaccination; participants with a history of previous SARS-CoV-2 infection had significantly higher anti-S1 IgG levels at two months compared to those without a history of infection. This evidence concerns the gene PSMD1 and infection.